透景生命(300642) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 145,099,766.40, representing a 22.30% increase compared to CNY 118,644,884.85 in the same period last year[3]. - Net profit attributable to shareholders decreased by 77.10% to CNY 5,270,134.33 from CNY 23,009,426.95 year-on-year[3]. - The net profit after deducting non-recurring gains and losses fell by 85.51% to CNY 3,065,114.09 compared to CNY 21,148,067.54 in the previous year[3]. - The company's basic and diluted earnings per share both decreased by 77.30% to CNY 0.032 from CNY 0.141 year-on-year[3]. - The net profit for the reporting period experienced a substantial decline compared to the previous year[12]. - Net profit for Q1 2022 was CNY 5,242,502.79, a decrease of 77.2% from CNY 23,009,426.95 in Q1 2021[18]. - The total comprehensive income for Q1 2022 was CNY 5,242,502.79, down from CNY 23,009,426.95 in Q1 2021[18]. Cash Flow - The net cash flow from operating activities improved significantly, reaching CNY 69,670,388.41, a 314.50% increase from a negative CNY 32,479,670.99 in the same period last year[3]. - The net cash flow from investment activities was CNY 58,012,186.31, a 226.75% increase compared to a negative CNY 45,769,375.97 in the previous year[9]. - The company experienced a 164.46% decrease in net cash flow from financing activities, amounting to CNY -6,513,798.27, due to share buybacks in the secondary market[9]. - Cash inflow from operating activities was CNY 194,746,627.61, compared to CNY 147,433,811.68 in Q1 2021, representing a growth of 32.0%[20]. - The net cash flow from operating activities was ¥69,670,388.41, a significant improvement compared to the previous period's net cash flow of -¥32,479,670.99[21]. - The net cash flow from investing activities was ¥58,012,186.31, recovering from a negative cash flow of -¥45,769,375.97 in the previous period[21]. - The company reported a cash outflow of ¥6,513,798.27 related to financing activities, compared to ¥158,487.66 in the previous period[21]. Assets and Liabilities - Total assets increased by 1.63% to CNY 1,523,258,716.68 from CNY 1,498,842,208.60 at the end of the previous year[3]. - The total liabilities at the end of Q1 2022 were CNY 126,601,913.16, an increase from CNY 102,586,486.72 at the beginning of the year[16]. - The company's current liabilities totaled CNY 106.15 million, up from CNY 81.44 million at the beginning of the year[15]. - Total equity attributable to shareholders of the parent company was CNY 1,394,259,335.82, slightly up from CNY 1,393,830,622.64 at the beginning of the year[16]. - The total assets of the company as of March 31, 2022, amounted to CNY 1,523.26 million, an increase from CNY 1,498.84 million at the beginning of the year[15]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 22,134[10]. - The largest shareholder, Yao Jian'er, holds 19.98% of the shares, amounting to 32,753,700 shares, with 2,826,000 shares pledged[10]. - The second-largest shareholder, Lingfei Group Co., Ltd., holds 9.28% of the shares, totaling 15,213,059 shares, with 5,580,000 shares pledged[10]. Operational Insights - The company's operating costs rose by 93.31% to CNY 71,603,875.56, primarily due to increased sales revenue and a higher proportion of agency products[8]. - The main products, tumor-related testing products, saw a significant decrease in procurement from clients in Beijing and Guangdong due to the pandemic[12]. - Despite the increase in marketing for COVID-19 testing instruments and consumables, the gross margin for these products is significantly lower than that of the company's proprietary testing reagents[12]. - The company expects sales of its main products to recover to normal levels following an improvement in the pandemic situation[12]. - Research and development expenses for Q1 2022 were CNY 16,680,429.10, an increase from CNY 15,540,837.73 in Q1 2021[17]. - The company reported a decrease in investment income to CNY 2,421,856.89 from CNY 4,253,121.99 in the previous year[17]. Other Financial Metrics - Total operating revenue for Q1 2022 was CNY 145,099,766.40, an increase of 22.3% compared to CNY 118,644,884.85 in the same period last year[17]. - Total operating costs for Q1 2022 were CNY 143,034,447.06, up 48.7% from CNY 96,225,957.17 in Q1 2021[17]. - The company did not receive any cash from investment in the current period, while it received ¥341,000,000.00 in the previous period[21]. - The report for the first quarter was not audited[22].